teclistamab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
rat origin 5706 2119595-80-9

Description:

MoleculeDescription

Molfile

Synonyms:

  • teclistamab
  • teclistamab-cqyv
  • tecvayli
  • JNJ-64007957
  • BCMAxCD3
Teclistamab is a full-size, IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA), which is expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. With its dual binding sites, teclistamab is able to draw CD3+ T cells in close proximity to BCMA+ cells, resulting in T cell activation and subsequent lysis and death of BCMA+ cells, which is mediated by secreted perforin and various granzymes stored in the secretory vesicles of cytotoxic T cells. This effect occurs without regard to T cell receptor specificity or reliance on major histocompatibility complex (MHC) Class 1 molecules on the surface of antigen presenting cells.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Aug. 23, 2022 EMA JANSSEN-CILAG INTERNATIONAL N.V.
Oct. 25, 2022 FDA JANSSEN BIOTECH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 906.94 42.96 187 1657 27786 90598817
Immune effector cell-associated neurotoxicity syndrome 411.16 42.96 75 1769 5693 90620910
Hypogammaglobulinaemia 70.78 42.96 20 1824 10654 90615949
Progressive multifocal leukoencephalopathy 67.40 42.96 21 1823 15634 90610969
Intervertebral discitis 61.57 42.96 15 1829 4505 90622098
Respiratory tract infection 58.40 42.96 27 1817 59051 90567552
COVID-19 57.09 42.96 38 1806 168805 90457798
Death 56.32 42.96 57 1787 456494 90170109

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 737.44 41.98 213 2273 44314 42574535
Immune effector cell-associated neurotoxicity syndrome 241.59 41.98 64 2422 9397 42609452
IVth nerve paralysis 133.25 41.98 24 2462 567 42618282
IgA nephropathy 131.67 41.98 30 2456 2344 42616505
COVID-19 128.01 41.98 81 2405 115867 42502982
Device related sepsis 69.90 41.98 20 2466 3867 42614982
Ureteric haemorrhage 49.53 41.98 9 2477 223 42618626
Hepatitis fulminant 48.55 41.98 16 2470 4943 42613906
Hypogammaglobulinaemia 48.00 41.98 20 2466 11871 42606978
Pneumonia 45.68 41.98 85 2401 422064 42196785
COVID-19 pneumonia 42.26 41.98 22 2464 21591 42597258

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 1274.76 34.77 327 3702 69979 110515291
Immune effector cell-associated neurotoxicity syndrome 466.50 34.77 108 3921 14674 110570596
COVID-19 163.89 34.77 105 3924 244955 110340315
IVth nerve paralysis 141.87 34.77 24 4005 635 110584635
IgA nephropathy 136.99 34.77 30 3999 3143 110582127
Hypogammaglobulinaemia 109.07 34.77 37 3992 20039 110565231
COVID-19 pneumonia 86.92 34.77 37 3992 37106 110548164
Pneumonia 84.20 34.77 129 3900 876585 109708685
Progressive multifocal leukoencephalopathy 75.91 34.77 30 3999 24926 110560344
Device related sepsis 65.80 34.77 20 4009 7627 110577643
Pyrexia 64.39 34.77 116 3913 898149 109687121
Adverse reaction 61.12 34.77 27 4002 29567 110555703
Ureteric haemorrhage 57.50 34.77 9 4020 144 110585126
Sepsis 54.11 34.77 63 3966 327283 110257987
Intervertebral discitis 50.53 34.77 16 4013 6974 110578296
Plasma cell myeloma 49.53 34.77 30 3999 62906 110522364
Hepatitis fulminant 47.35 34.77 16 4013 8544 110576726
Respiratory tract infection 45.97 34.77 30 3999 71587 110513683
Death 43.37 34.77 85 3944 698784 109886486
Plasmacytoma 42.03 34.77 13 4016 5249 110580021
Cytomegalovirus infection reactivation 42.00 34.77 18 4011 18315 110566955
Plasma cell myeloma refractory 39.30 34.77 10 4019 1991 110583279
Bacterial sepsis 36.90 34.77 14 4015 10412 110574858
Tachypnoea 36.83 34.77 21 4008 39374 110545896
Campylobacter test positive 36.30 34.77 6 4023 137 110585133

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX24 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelotuzumabelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Relapsed or refractory multiple myeloma indication 109989006 DOID:9538




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
T-cell surface glycoprotein CD3 Surface antigen ANTIBODY BINDING Kd 7.55 DRUG LABEL DRUG LABEL
Tumor necrosis factor receptor superfamily member 17 Tumour-associated antigen ANTIBODY BINDING Kd 9.74 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:757981 CHEBI
CHEMBL4594505 ChEMBL_ID
C000731928 MESH_SUPPLEMENTAL_RECORD_UI
12233 IUPHAR_LIGAND_ID
DB16655 DRUGBANK_ID
278171000202105 SNOMEDCT_US
4041792 VANDF
4041793 VANDF
C5235398 UMLSCUI
10928 INN_ID
D12177 KEGG_DRUG
362676 MMSL
41040 MMSL
d09938 MMSL
019216 NDDF
54534MX6Z9 UNII
2619425 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TECVAYLI HUMAN PRESCRIPTION DRUG LABEL 1 57894-449 INJECTION 10 mg SUBCUTANEOUS BLA 31 sections
TECVAYLI HUMAN PRESCRIPTION DRUG LABEL 1 57894-450 INJECTION 90 mg SUBCUTANEOUS BLA 31 sections